PlainRecalls
FDA Drug Moderate Class II Terminated

Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Reported: September 16, 2020 Initiated: August 24, 2020 #D-0012-2021

Product Description

Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Reason for Recall

CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
103,940 bottles
Distribution
Nationwide in the U.S. and Puerto Rico.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.. Recalled by Teva Pharmaceuticals USA. Units affected: 103,940 bottles.
Why was this product recalled?
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 16, 2020. Severity: Moderate. Recall number: D-0012-2021.